null

null

null

null

null

null

null

null

null

Pre-revenue clinical-stage biotech; minimal debt, primarily equity-financed; ~$200M+ cash runway; low leverage ratio near 0x EBITDA

Negligible direct debt interest sensitivity; rising rates increase cost of future equity/debt raises and compress biotech valuations via higher discount rates

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API sourcing from contract manufacturers (likely China/India pharma APIs) and specialized CDMO facilities in EU/US represent top two chokepoints

Primarily US-focused clinical stage; no significant international revenue; sovereign currency devaluation exposure is minimal at this stage

Operations concentrated in US; clinical trials may span EU and Asia-Pacific; no material international revenue exposure to currency devaluation risk currently

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single CDMO or CRO likely represents >30% of operational input; non-substitutable in short term given regulatory filing continuity requirements

Clinical-stage biopharma; cloud disruption would impair data/trial management but not core drug IP; 6-12 month recovery feasible with significant cost

Secondary model involves potential licensing/partnership deals; cloud termination would delay regulatory submissions and partner data sharing materially

API coupling risk moderate; reliance on specialized clinical data platforms (Medidata, Veeva) creates switching friction but alternatives exist in 12-18 months

Revenue model is drug development/licensing; equity clearly a security; primary revenue (milestone payments, future royalties) is not a Howey instrument—low index risk

Very High

Clinical trial patient data subject to GDPR (EU trials) and HIPAA; CCPA exposure limited; moderate compliance burden with standard pharma data governance protocols

Low antitrust risk currently; pre-commercial stage with no market dominance; future orphan drug exclusivity or patent thickets could attract scrutiny post-launch

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~0% recurring revenue currently; 100% transactional/milestone-based from partnerships (e.g., AstraZeneca collaboration); no subscription revenue streams

Monetization via upfront payments, development milestones, and future royalties on partnered assets; supplemented by potential future product sales

No commercial pricing yet; future pricing will follow specialty/rare disease biologic model (~$100K-$500K+ annually) with payer negotiation dependency

Moderate-to-high potential pricing power if lead assets achieve orphan/rare disease designation with limited competition; payer pushback remains key risk

Target gross margin 70-85% at commercial stage, typical for biologics/specialty pharma post-COGS normalization; currently negative (R&D burn phase)

No free-rider leakage issue; IP-protected drug pipeline with patent and regulatory exclusivity barriers; partnership agreements contain exclusivity clauses

Revenue growth is sublinear to headcount; milestone and royalty income scales without proportional headcount increase; R&D headcount grows slower than revenue potential

Marginal cost of incremental revenue (milestones/royalties) near zero post-approval; primary fixed costs are R&D and G&A; highly scalable post-commercialization

null

At 10x scale (post-commercialization), CAC shifts to payer/physician access costs; specialty pharma sales force economics require ~$500K-$1M revenue per rep

No meaningful network effects; drug efficacy and IP protection are competitive moats, not user-scale dynamics; network effects not applicable to this model

-98.5% Return on Assets (Negative equity)

Moderate-to-high recession resistance; rare/serious disease treatments maintain demand; funding risk increases in downturn as equity markets tighten for biotech

Primary customers post-commercialization: specialty physicians and hospital systems treating rare/inflammatory diseases; current partners include large pharma (AstraZeneca)

Secondary customers: government payers (Medicare/Medicaid), private insurers, and rare disease patient advocacy-driven formulary access channels

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.2% CapEx / Revenue (Low-CapEx Asset-Light)

0001953926

ZBIO